As the flagship journal of the American Cancer Society, CA publishes the latest cancer statistics, ACS guidelines, and reviews on the current state of cancer.
New @AmericanCancer guideline for early detection of prostate cancer proactively recommends screening for average-risk men ages 50-69 and high-risk men ages 45-69, while redefining what happens after an elevated PSA.
🔗: acsjournals.onlinelibrary.wi…@OncoAlert@ACSNews
JUST IN: @AmericanCancer (ACS) updates their guidance about routine PSA screening for #prostatecancer, moving off "shared decision-making".
This is a major shift since the last ACS recommendations in 2010:
1) High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69
2) Average risk: PSA every 2 years, ages 50–69. American Cancer Society
3) Non-Black men with 1 first-degree relative diagnosed ≥65: PSA every 2 years, ages 45–69.
4) Age 70–74: individualized decision; if screening continues, every 2 years.
5) Age ≥75: generally no screening; very healthy men 75–79 may discuss continued screening.
6) No screening ≥80 and no screening at any age with life expectancy <10 years.
@CACancerJournal@DanaFarber_GU@harvardmed@OpenMedInsights
Link: acsjournals.onlinelibrary.wi…
For years, #CancerCachexia had few options. Now, several therapies are in development. Join Prof. Jeffrey Crawford, Prof. Egidio Del Fabbro and Prof. Rony Dev live as they discuss treatments on November 17.
11 AM EST | 4 PM GMT | 5 PM CET
Register: event.on24.com/wcc/r/5500473…
Help your patients understand the newest @AmericanCancer prostate cancer guideline on early detection. Our Patient Page breaks down available tests, recommendations, and treatment options in a concise, easy-to-read format.
Free download: acsjournals.onlinelibrary.wi…@OncoAlert#PCSM
🚨 Major shift: @AmericanCancer now directly recommends routine PSA screening for #prostatecancer, moving off pure shared decision-making 🚨
@CACancerJournal
📋 Average risk: PSA every 2 yrs, ages 50-69
📋 High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69
📋 Non-Black w/ one first-degree relative dx ≥65: every 2 yrs, ages 45-69
🔬 Age-adjusted elevated = PSA ≥3.0 (ages 45-69) or ≥6.5 (70-74); repeat in 2 wks to 3 mo, then MRI and/or validated biomarker before biopsy
🛑 70-74 individualized; not recommended ≥75 or if life expectancy <10 yrs
⚠️ Still requires informed consent on benefits, limits, and harms, and departs from USPSTF’s grade C for 55-69
🎯 ACS has moved from “discuss it” to “do it” for average-risk men 50-69 and high-risk men from 45, its biggest change since 2010
🔗 doi.org/10.3322/caac.70112@UroOnc@urotoday@UrologyTimes@PCF_Science@AmerUrological
The management of early stage NSCLC has evolved beyond historical reliance on anatomic resection into a sophisticated, biology-driven discipline. This review looks toward a risk-adaptive paradigm in the era of biologic precision #LungCancerAwarenessMonthacsjournals.onlinelibrary.wi…
People who smoke or used to smoke are at higher risk for #LungCancer. While quitting smoking lowers risk over time, it is still higher than among people who have never smoked.
Download our free #PatientPage on screening for lung cancer: acsjournals.onlinelibrary.wi…@OncoAlert
Many oncology clinics lack gender-affirming practices. @CancerCareMASCC offer guidance on cancer care for transgender & gender-diverse people:
✅ Avoid gender assumptions
✅ Use affirmed names/pronouns
✅ Provide gender-neutral facilities
acsjournals.onlinelibrary.wi…@OncoAlert
Submit your phase 3 trials to CA for rapid review and publication! As the highest-impact-factor journal among oncology titles, CA aims to give study teams the broadest possible reach without restrictive paywalls.
More info:
acsjournals.onlinelibrary.wi…@KekoaMDPhD@Dr_R_Kurzrock
New Perspectives: Patients receiving virtual sustained treatment had a 6-month quit rate nearly double that of patients receiving NCI quitline referrals. Patients using VST were nearly 4x more likely to report smoking cessation medication use.
acsjournals.onlinelibrary.wi…@OncoAlert
New in Perspectives: Research in Context 📖 New study challenges current standards of continuous-duration therapy and suggests that many standard-risk patients with newly diagnosed multiple myeloma may be able to stop treatment after 2 years.
acsjournals.onlinelibrary.wi…@OncoAlert